Loading patent…
OwnerHiromitsu NAKAUCHI, Tohinobu NISHIMURAinventors
Estimating the term…
Compositions, methods, and kits are provided for producing rejuvenated cytotoxic T cells (CTLs) specific for mutated neo-antigen epitopes expressed on cancerous cells, including epidermal growth factor receptor (EGFR) and KRAS neo-antigen epitopes. Antigenspecific CTLs are rejuvenated by reprogramming them into induced pluripotent stem cells (IPSCs) using Yamanaka factors and redifferentiating them back into CTLs while expanding their numbers. After redifferentiation, the IPSC-derived rejuvenated CTLs retain the antigen specificity of the original CTLs from which they were derived, but have the advantage of having longer telomeres and higher proliferative activity than the original CTLs. Pharmaceutical compositions comprising such IPSC-derived rejuvenated CTLs are useful for treating cancers expressing the mutated neo-antigen epitopes recognized by the original CTLs.
A method of cellular immunotherapy for treating a subject for a cancer expressing a mutated epidermal growth factor receptor (EGFR) or KRAS neo-antigen epitope, the method comprising:
(canceled)
(canceled)
9-10. (canceled)
15-16. (canceled)
(canceled)
21-22. (canceled)
24-29. (canceled)
A method of producing an induced pluripotent stem cell (IPSC)-derived rejuvenated cytotoxic T cell (CTL) specific for a mutated EGFR or KRAS neo-antigen epitope, the method comprising:
(canceled)
35-37. (canceled)
40-51. (canceled)
Dependencies are inferred from the claim text.